Hospital
The Charlotte-Mecklenburg Hospital Authority
The Charlotte-Mecklenburg Hospital Authority was paid $58.00M by Medicaid between Jan 2018 and Dec 2024, across 154 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
SHELBY, NC 28150
SHELBY, NC 28150
33aNPI1326442336assigned 10/20/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$58.00M
24GClaims797,372
24DCodes billed154
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#7 of 92
Median peer was paid$11.47M
This provider vs. median5.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 99,028 | $4.12M | |
| 2019 | 113,193 | $5.93M | |
| 2020 | 93,130 | $5.60M | |
| 2021 | 118,045 | $9.22M | |
| 2022 | 113,741 | $10.07M | |
| 2023 | 132,131 | $11.33M | |
| 2024incomplete | 128,104 | $11.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 86,686 | 81,748 | $23.10M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 69,195 | 64,735 | $17.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 25,004 | 23,490 | $5.67M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 19,311 | 18,388 | $1.21M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 25,586 | 23,737 | $1.03M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.6% | 6,744 | 6,365 | $952K |
| T1016 | Case management, each 15 minutes | 1.3% | 10,561 | 3,304 | $736K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 36,195 | 33,998 | $714K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 27,136 | 22,674 | $689K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 7,073 | 6,503 | $609K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,092 | 16,996 | $516K |
| J3490 | Unclassified drugs | <1% | 77,299 | 45,150 | $444K |
142 more codes
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 431 | $420K |
| 80053 | Comprehensive metabolic panel | <1% | 31,057 | $334K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,783 | $334K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 455 | $262K |
| T2041 | Supports brokerage, self-directed, waiver; per 15 minutes | <1% | 7,498 | $260K |
| G0378 | Hospital observation service, per hour | <1% | 1,765 | $222K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,875 | $222K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,583 | $192K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,857 | $166K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 842 | $156K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 28,372 | $152K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 23,731 | $149K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,772 | $130K |
| 81001 | <1% | 37,074 | $128K | |
| 81025 | <1% | 15,077 | $119K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,316 | $117K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,789 | $115K |
| 85027 | <1% | 17,273 | $99K | |
| 80047 | <1% | 11,202 | $83K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,945 | $73K |
| 97597 | <1% | 1,918 | $66K | |
| 84484 | <1% | 8,133 | $63K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 27 | $60K |
| 62323 | <1% | 266 | $57K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,965 | $56K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 720 | $51K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,253 | $51K |
| 83690 | <1% | 7,196 | $50K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,847 | $45K |
| B4150 | Enteral formula, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit | <1% | 657 | $40K |
| A4554 | Disposable underpads, all sizes | <1% | 1,232 | $39K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,370 | $34K |
| T4527 | Adult sized disposable incontinence product, protective underwear/pull-on, large size, each | <1% | 457 | $30K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,579 | $29K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,731 | $26K |
| 20610 | <1% | 281 | $24K | |
| 59025 | Fetal non-stress test | <1% | 199 | $23K |
| B4154 | Enteral formula, nutritionally complete, for special metabolic needs, excludes inherited disease of metabolism, includes altered composition of proteins, fats, carbohydrates, vitamins and/or minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit | <1% | 362 | $23K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 354 | $23K |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 16 | $20K |
| 11045 | <1% | 228 | $20K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 69 | $19K |
| T4526 | Adult sized disposable incontinence product, protective underwear/pull-on, medium size, each | <1% | 294 | $19K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,586 | $16K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 158 | $15K |
| 81003 | <1% | 4,846 | $15K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,331 | $15K |
| 27096 | <1% | 110 | $14K | |
| T4535 | Disposable liner/shield/guard/pad/undergarment, for incontinence, each | <1% | 612 | $14K |
| 94761 | <1% | 878 | $14K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,436 | $14K |
| T4528 | Adult sized disposable incontinence product, protective underwear/pull-on, extra large size, each | <1% | 236 | $14K |
| 43248 | <1% | 47 | $12K | |
| A4927 | Gloves, non-sterile, per 100 | <1% | 675 | $11K |
| 80076 | <1% | 1,553 | $11K | |
| 83735 | <1% | 1,542 | $10K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 245 | $9K |
| 93017 | <1% | 59 | $9K | |
| T4524 | Adult sized disposable incontinence product, brief/diaper, extra large, each | <1% | 93 | $8K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 2,318 | $8K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 38 | $7K |
| 77336 | <1% | 143 | $7K | |
| T4523 | Adult sized disposable incontinence product, brief/diaper, large, each | <1% | 84 | $7K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $7K |
| 83605 | <1% | 834 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 225 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 225 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 161 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,529 | $6K |
| 82803 | <1% | 373 | $5K | |
| 87430 | <1% | 356 | $5K | |
| 82248 | <1% | 985 | $5K | |
| 80061 | Lipid panel | <1% | 443 | $5K |
| 87070 | <1% | 346 | $4K | |
| 96376 | <1% | 746 | $4K | |
| 20553 | <1% | 42 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,700 | $4K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,318 | $4K |
| T4522 | Adult sized disposable incontinence product, brief/diaper, medium, each | <1% | 58 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,378 | $4K |
| 80320 | <1% | 114 | $4K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 60 | $3K |
| 82728 | <1% | 294 | $3K | |
| 0002A | <1% | 102 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 202 | $3K |
| 29581 | <1% | 38 | $3K | |
| 88342 | <1% | 71 | $3K | |
| 94760 | <1% | 593 | $3K | |
| 82962 | <1% | 725 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,281 | $2K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,044 | $2K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 770 | $2K |
| 0001A | <1% | 118 | $2K | |
| C1769 | Guide wire | <1% | 48 | $2K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 17 | $2K |
| 93798 | <1% | 59 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 40 | $2K |
| 85014 | <1% | 615 | $2K | |
| 83880 | <1% | 67 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 991 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 837 | $2K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 395 | $1K |
| A4335 | Incontinence supply; miscellaneous | <1% | 222 | $1K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 74 | $1K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 826 | $1K |
| 96367 | <1% | 174 | $933.94 | |
| 84466 | <1% | 104 | $880.74 | |
| 99199 | Unlisted special service, procedure or report | <1% | 151 | $855.63 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 69 | $816.98 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 728 | $580.72 |
| 87210 | <1% | 124 | $566.92 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $502.06 |
| 83540 | <1% | 105 | $455.60 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 462 | $435.42 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 75 | $409.14 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 225 | $387.52 |
| 82607 | <1% | 27 | $384.72 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 83 | $351.56 |
| T2025 | Waiver services not otherwise specified | <1% | 18 | $314.65 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28 | $284.34 |
| 85610 | <1% | 73 | $257.91 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 121 | $231.16 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 50 | $204.40 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 65 | $192.28 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 54 | $188.57 |
| 82746 | <1% | 15 | $182.18 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 50 | $181.17 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 46 | $155.43 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 101 | $123.18 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $110.51 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 182 | $108.35 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 50 | $99.99 |
| 87081 | <1% | 15 | $83.22 | |
| 81002 | <1% | 17 | $33.50 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 28 | $33.20 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 18 | $22.59 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 21 | $16.98 |
| A9270 | Non-covered item or service | <1% | 8,940 | $6.06 |
| 91300 | 0% | 221 | $0.00 | |
| 36591 | 0% | 822 | $0.00 | |
| 90686 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.